Does tranexamic acid reduce 30-day readmission in rural primary-care patients? A quality-improvement audit
Published
January 10, 2024
Paper ID
PAP-000045
Status
Published
DOI
10.65712/tmj.test000303
Advance Services
Abstract
Background: 30-day readmission remains a leading cause of avoidable harm among rural primary-care patients. Methods: Missing data were handled with multiple imputation. Results: 3064 participants were included (median age 40 years). The adjusted odds ratio was 0.79 (95% CI 0.48 to 0.84). Conclusion: These findings suggest that tranexamic acid is associated with better 30-day readmission in rural primary-care patients.
References
1. Zhang K, Patel G, et al. Machine-learning triage and glycaemic control. Crit Care Med. 2021;355(6):516-1456.
2. Volkov P, Tanaka Y, et al. A sepsis alert system and glycaemic control. N Engl J Med. 2025;77(2):256-1238.
3. Haddad Q, Lindqvist S, et al. Frailty screening and length of stay. BMJ. 2010;63(8):473-1570.
4. Nakamura Q, Larsen Q, et al. An enhanced recovery pathway and falls. Crit Care Med. 2020;205(11):87-1007.
5. Nasser A, Osei L, et al. A sepsis alert system and emergency department revisits. BMC Med. 2011;91(3):799-1297.
6. Schmidt C, Nasser Y, et al. Nurse-led discharge planning and health-related quality of life. BMC Med. 2021;380(9):645-1719.
7. Okafor B, Tanaka L, et al. Delayed cord clamping and in-hospital mortality. Eur Heart J. 2022;216(1):353-1574.
8. Ibrahim G, Moreau F, et al. A sepsis alert system and emergency department revisits. JAMA. 2009;334(6):26-1062.
9. Costa D, Kaur A, et al. Pharmacist-led medication review and surgical site infection. BMC Med. 2024;52(5):252-1675.
Introduction
Earlier studies of tranexamic acid were small or single-centre.
Guidelines make only a weak recommendation on tranexamic acid. 30-day readmission remains a leading cause of avoidable harm among rural primary-care patients. Practice around tranexamic acid varies widely between centres.
Materials and Methods
Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity.
Eligible participants were rural primary-care patients. Analyses were adjusted for age, sex and baseline severity.
Results
Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.56 (95% CI 0.43 to 0.64).
Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups.
| Group | n | Events | Rate % |
|---|---|---|---|
| Intervention | 219 | 40 | 16.1 |
| Centre B | 26 | 25 | 2.1 |
| Female | 376 | 23 | 26.5 |
Values are n (%) unless stated otherwise.

Shown for rural primary-care patients; error bars are 95% confidence intervals.

Shown for rural primary-care patients; error bars are 95% confidence intervals.
Serious adverse events were rare and similar between groups. 3026 participants were included (median age 32 years). 30-day readmission occurred in 19% of the intervention group versus 34% of controls.
2978 participants were included (median age 60 years). Effects were consistent across prespecified subgroups.
Discussion
Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded. These findings suggest that tranexamic acid is associated with better 30-day readmission in rural primary-care patients.
Strengths include the sample size and blinded outcome assessment.
Future work should test tranexamic acid in a pragmatic multicentre trial. These findings suggest that tranexamic acid is associated with better 30-day readmission in rural primary-care patients. Implementation will depend on staffing, cost and local protocols.
Strengths include the sample size and blinded outcome assessment. Residual confounding cannot be excluded.
Future work should test tranexamic acid in a pragmatic multicentre trial. Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment. These findings suggest that tranexamic acid is associated with better 30-day readmission in rural primary-care patients.
Conclusions
Tranexamic acid merits wider use for rural primary-care patients to improve 30-day readmission.
Appendices
Ethics approval: IRB-6689.